<DOC>
	<DOCNO>NCT00381810</DOCNO>
	<brief_summary>This Phase II/III open label , single-arm , multicenter , extension study evaluate safety efficacy rituximab administer schedule basis every 6 month course 1 year reassessment response 12 month . This study open participant previously enrol Genentech Study U2971g .</brief_summary>
	<brief_title>A Study Evaluate Safety Rituximab Retreatment Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Subjects systemic lupus erythematosus ( SLE ) participate satisfactorily complete Week 52 evaluation Study U2971g . For partial clinical response ( PCR ) nonclinical response ( NCR ) , active disease screening define one domains British Isles Lupus Assessment Group ( BILAG ) A score 2 domain BILAG B score . Subjects withdraw study U2971g protocol noncompliance safety issue . Any safety concern potentially attribute rituximab investigator 's opinion would jeopardize subject safety . Subjects withdraw study U2971g receive rituximab rescue therapy outside protocol . Subjects , investigator 's opinion , demonstrate clinical improvement Week 52 study U2971g propose therapy would represent risk without benefit . Unstable subject thrombocytopenia experience high risk develop clinically significant bleed organ dysfunction require therapy plasmapheresis acute blood platelet transfusion . Pregnant woman nurse ( breastfeed ) mother . History severe , allergic , anaphylactic reaction humanize murine monoclonal antibody . Known active infection kind ( exclude fungal infection nail bed ) major episode infection require hospitalization treatment intravenous ( IV ) antibiotic within 8 week screen oral antibiotic within 2 week prior screen . History cancer , include solid tumor , hematological malignancy , carcinoma situ . Major surgery within 4 week prior screen . Intolerance contraindication oral IV corticosteroid . Positive hepatitis B surface antigen ( BsAg ) hepatitis C serology . Receipt live vaccine within 28 day prior treatment .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Rituxan</keyword>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
</DOC>